Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Pharmaceutical / Industry				P04467 NCT00539968


2.		Lonafarnib in Metastatic Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				Over 18				Other, Pharmaceutical / Industry				HOG BRE07-126 NCT00773474

Last Modified: 12/27/2004 First Published: 8/24/2003


3.		Phase I Study of Lonafarnib, Trastuzumab (Herceptin®), and Paclitaxel in Patients With HER2/neu-Overexpressing Stage IIIB, IIIC, or IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other, Pharmaceutical / Industry				EORTC-16023-10051 SPRI-P01900, NCT00068757

Last Modified: 8/23/2007 First Published: 4/23/2004


4.		Phase I Study of Lonafarnib and Temozolomide in Patients With Recurrent Primary Supratentorial Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				Over 18				Other, Pharmaceutical / Industry				EORTC-16027 EORTC-26023, SPRI-P03174, NCT00083096


5.		Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment				Active				18 and over				Other				174-2004 EU841-03, NCT00288444

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute